Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
A good year it will be
Why has Wallace refused to pay the JAMS fee?
WILL WALLACE BE HEADED FOR JAIL due to his tortious interference of GOSY? or will there just be large financial payout to GOSY? can someone explain?
Thank you for the truth with evidence
Bill gates is the largest holder of microsoft stock with like 6%, so I guess he has that in common. What a loser he dropped out of Harvard. Bashing people's past is easy. However, change occurs with the future. Change is what's scares people.
Great point
Also agree, should see nice spike (fingers crossed)
Maybe the deal was worth letting go? With Wallace and Macleod involved, who knows what wrong turns it began to take.
None of these events have anything to do with the Chinese deal. Shareholders are happy to know this.
How do you know what the deal looks like?
What inside information are you basing this guess on?
Indeed, Wallace and Macleod are trying desperately to bring down the company. Fortunately, the Chinese don't care about them. Good for us shareholders huh?
It's the most important and most difficult component to any selv navigation devise or application. Could be used in cars, golf carts, industrial equip, you name it.
Should see a move here very soon, IMO
Global interest in the software as well. Like everything else, the Chinese will make it and the US will buy It.
If you think you can buy a better stock at. .007 then feel free. If you are that concerned with consistent revenue, buy a $30.00 stock. Good luck making a 20,000% return or whatever. Funny why there seems to be confusion with risk and reward with pinks.
Good things ahead for LVLT. looking good at these levels
Transparent like a golf course construction project should be with the citizens around it?
No matter, GOSY seems to have everything under control. Just because someone yells fire, doesn't mean your in danger.
you hearing any buzz about GOSY?
Neuralstem's NSI-189 Trial in Major Depressive Disorder Receives FDA Approval to Advance to Phase Ib
Neuralstem, Inc. (NYSE Amex: CUR) announced that it has been approved by the Food and Drug Administration to advance to Phase Ib in its ongoing clinical trial to test its novel neuroregenerative compound, NSI-189, for the treatment of major depressive disorder (MDD). Phase Ib will test the safety and tolerability of the drug in depressed patients. NSI-189 is a proprietary new chemical entity discovered by Neuralstem that stimulates new neuron growth in the hippocampus, an area of the brain that is believed to be involved in MDD as well as other diseases and conditions, such as Alzheimer's disease and post-traumatic stress disorder (PTSD).
"We are pleased to be approved to begin testing NSI-189 in patients who suffer from depression," said Karl Johe, PhD, Chief Scientific Officer and Chairman of Neuralstem's Board of Directors. "Loss of hippocampal volume is a known characteristic in depressed patients. NSI-189 stimulates neurogenesis and increases hippocampal volume in healthy adult mice, at the same time reversing behavioral symptoms in mouse depression models, so it could address depression at the source."
"It is exciting to see a new class of drugs that potentially offers a novel and different approach to this disease moving into patients," said Maurizio Fava, MD, Slater Family Professor of Psychiatry at Harvard Medical School and Executive Vice Chair of the Department of Psychiatry at Massachusetts General Hospital. Dr. Fava, one of the world's leading researchers in MDD, helped design the Neuralstem trial.
About NSI-189
Neuralstem's technology enabled the creation of neural stem cell lines from many areas of the human CNS, including the hippocampus. The hippocampus is a part of the brain involved in memory and the generation of new neurons. It is also implicated in several major neurological and psychiatric diseases. From its hippocampal neural stem cell lines, Neuralstem has created virtually unlimited amounts of mature human neurons and glia in laboratory dishes. These can be used to mimic the natural brain environment in order to test drug effects.
Neuralstem has been engaged in its own drug discovery program with these human hippocampal stem cell lines since 2000. In 2009, Neuralstem was granted U.S. patents on four first-in-class chemical entities that boost the generation of new neurons. NSI-189, the first of these to be in a clinical trial, significantly stimulates the generation of new hippocampal neurons (neurogenesis) in vitro and in animal models, above and beyond the neural stem cells' innate differentiation.
NSI-189 is the lead compound in Neuralstem's neuroregenerative small molecule drug platform, which the company plans to develop into orally administered drugs for MDD and other psychiatric disorders, such as Alzheimer's disease, anxiety, bipolar disorder and post traumatic stress disorder.
NSI-189 stimulated neurogenesis of human hippocampus-derived neural stem cells in-vitro. In healthy normal adult mice, NSI-189 stimulated neurogenesis in the hippocampus and significantly increased its volume, apparently by increasing its synaptic network after 28 days of daily oral administration. In mouse models of depression, NSI-189 significantly improved behavioral responses associated with depression. In humans, NSI-189 may reverse the human hippocampal atrophy seen in MDD and other disorders and reverse their symptoms. This program has received significant support from both the Defense Advanced Research Projects Agency (DARPA) and the National Institutes of Health (NIH).
About the Trial
The NSI-189/MDD trial is a randomized, double-blind, placebo-controlled, multiple-dose escalating trial evaluating the safety, tolerability, pharmacokinetics and pharmacodynamic effect of NSI-189 in the treatment of MDD. Phase Ia tested escalating doses of single administration of NSI-189 in healthy patients. Phase Ib will test the safety of escalating doses of NSI-189 for 28 daily administrations in 24 depressed patients. The Phase Ib portion of the trial is expected to take approximately six months to complete.
About Neuralstem
Neuralstem's patented technology enables the ability to produce neural stem cells of the human brain and spinal cord in commercial quantities, and the ability to control the differentiation of these cells constitutively into mature, physiologically relevant human neurons and glia. Neuralstem is in an FDA-approved Phase I safety clinical trial for amyotrophic lateral sclerosis (ALS), often referred to as Lou Gehrig's disease and has been awarded orphan status designation by the FDA.
In addition to ALS, the company is also targeting major central nervous system conditions with its cell therapy platform, including spinal cord injury, ischemic spastic paraplegia, chronic stroke, and Huntington's disease. The company has submitted an IND (Investigational New Drug) application to the FDA for a Phase I safety trial in chronic spinal cord injury.
Neuralstem also has the ability to generate stable human neural stem cell lines suitable for the systematic screening of large chemical libraries. Through this proprietary screening technology, Neuralstem has discovered and patented compounds that may stimulate the brain's capacity to generate new neurons, possibly reversing the pathologies of some central nervous system conditions. The company has received approval from the FDA to conduct a Phase Ib safety trial evaluating NSI-189, its first small molecule compound, for the treatment of major depressive disorder (MDD). Additional indications could include schizophrenia, Alzheimer's disease and bipolar disorder.
Surprised we havent seen a slight jump up
Good news
Maybe ill get a stickie...
Yea people need to know the truth
thanks, it took me a while to do my DD on that one.
I heard the company spends untold amounts of money in paper each year. Geez.
I wonder if GOSY will have sustaining revenues in the 1st QTR of 2012?
GeckoSystems stock is quoted in the U.S. over-the-counter (OTC) markets, on the Pink OTC Current Information tier, under the ticker symbol GOSY.
i heard that Wallace begged to come back on his hands and knees because he knew nobody else would hire him.
Fired employees who were fired because they were worthless?
I cant give legal advise, you should ask a lawyer...a good one that is. BTW, i didn't say "no one".
Only a opinion, but i would say this was a fruitful meeting.
http://www.geckosystems.com/investors/press_releases/20101220_GeckoSystems_Sr_Japanese.php
I know, its just silly the questions. This board is damaged, good thing the Chinese care little for blog boards.
Rudolph the red nosed GOSY - please put in iBox - great DD. here is a link to the website
http://www.geckosystems.com/
Excellent opportunity
GOSY is great
I don't see any information regardIng the rObotics industry and the imminent relationships that will result in revenue channels for the company. Share structure is easily rectified. I hope the criticism is not hInged only on share structure with so many governments and companies knocking on GOSY's doorstep. I guess when that's all you got...
Hey I got this pinkie that is having share structure problems this board poster said....
CHINA GOVERNMENT officials said "LOL"
If sales revenue is a prerequisite of your investing decisions, pink sheets are risky. Its really not impressive DD to find a company with no current revenue, then point it out. Few pinkies have revenues and most are shells. GOSY is not. Apple was a great buy at $375 IMO if you are looking for revenue. Once revenues are declared at GOSY, which they will, the risk will be rewarded. I would think this would be in Wallace's best interest.
Or if you are an intelligent trader or investor who understands the concept of buy low, sell high. It's been know. To work.